Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells

Cell Growth and Differentiation

Volumn 11, Issue 9, 2000, Pages 467-474

  Satyamoorthy, K ^a   Chehab, N H ^a   Waterman, M J F ^a   Lien, M C ^a   El Deiry, W S ^a   Herlyn, M ^a   Halazonetis, T D ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; DNA DAMAGE; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BASE SEQUENCE; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; MELANOMA; PHOSPHORYLATION; PROTEIN P53; RADIATION TOLERANCE; SERINE; SIGNAL TRANSDUCTION; SUPPORT, U.S. GOV'T, P.H.S.; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TYROSINE 3-MONOOXYGENASE;

EID: 0033795383     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Apoptosis in cancer therapy: Crossing the threshold
2. p53 Status and the efficacy of cancer therapy in vivo
3. p53, The cellular gatekeeper for growth and division
4. Participation of p53 protein in the cellular response to DNA damage
5. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
6. p53 Is required for radiation-induced apoptosis in mouse thymocytes
7. Thymocyte apoptosis induced by p53-dependent and independent pathways
8. Mutational analysis of the human p53 gene in malignant melanoma
9. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma
10. Mutation and expression of the p53 gene in malignant melanoma cell lines
11. Mutation and expression of TP53 in malignant melanomas
12. Mutation and expression of the p53 gene in human malignant melanoma
13. TP53 allele loss, mutations and expression in malignant melanoma
14. Absence of p53 gene mutations in cutaneous melanoma
15. Analysis of p53 in human cutaneous melanoma cell lines
16. Radiation therapy for malignant melanoma
17. Malignant melanoma: The role of radiation therapy revisited
18. Oncoprotein Mdm2 conceals the activation domain of tumour suppressor p53
19. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
20. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
21. 1 by stabilizing p53
22. DNA damage-induced activation of p53 by the checkpoint kinase chk2
23. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
24. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells
25. The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate
26. p53 Transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle
27. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
28. DNA damage-induced phosphorylation of p53 alleviates inhibition by Mdm2
29. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage
30. 20 of human p53 in the negative regulation of p53 by Mdm2
31. Mdm2 promotes the rapid degradation of p53
32. Regulation of p53 stability by mdm2
33. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins
34. WAF1, a potential mediator of p53 tumor suppression
35. A p53-dependent mouse spindle checkpoint
36. Expression of Bcl-x(L) and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage
37. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function
38. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption
39. Overexpression of p53 is a late event in the development of malignant melanoma
40. p53 Immunoreactivity in human malignant melanoma and dysplastic naevi
41. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: Increased immunopositivity in hereditary melanoma
42. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma
43. An abnormality in the p53 pathway following γ-irradiation in many wild-type p53 human melanoma lines
44. The p53-mdm2 autoregulatory feedback loop
45. p53 And mdm-2 expression in malignant melanoma: An immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors
46. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage
47. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control
48. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation
49. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
50. The Ink4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53
51. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppressor pathways
52. Germline p16 mutations in familial melanoma
53. A cell cycle regulator potentially involved in genesis of many tumor types
54. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
55. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
56. 14-3-3 Proteins are part of an abscisic acid-VIVIPAROUS1 (VP1) response complex in the Em promoter and interact with VP1 and EmBP1
57. Association of the TLX-2 homeodomain and 14-3-3 εsignalling proteins
58. Specific interactions with TBP and TFIIB in vitro suggest that 14-13-3 proteins may participate in the regulation of transcription when part of a DNA binding complex
59. Many faces of ATM: Eighth International Workshop on Ataxia-Telangiectasia
60. Characteristics of cultured human melanocytes isolated from different stages of tumor progression
61. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug
62. Adenovirus infection enhances killing of melanoma cells by a mitotoxin
63. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants
64. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias
65. Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry